Alcon acquires Neurotech Pharmaceuticals for $550 million to expand retinal disease portfolio

Alcon is acquiring Neurotech Pharmaceuticals for a reported $550 million, adding Encelto and an encapsulated-cell therapy platform to its retinal disease portfolio.

The transaction will expand Alcon's ophthalmic therapeutics activities through Neurotech Pharmaceuticals' Encelto product and encapsulated-cell technology, complementing Alcon's established surgical and vision-care businesses.

The reported acquisition value is $550 million, although the supplied announcement summary does not specify the consideration structure, closing conditions or a confirmed completion date.

Field	Content
Article Type	Deals
Acquirer	Alcon
Target	Neurotech Pharmaceuticals
Deal Type	Acquisition
Reported Transaction Value	$550 million
Transaction Status	Acquisition announced; completion status not confirmed in supplied summary
Announcement Period	21-22 October 2026
Therapeutic Area	Ophthalmology; retinal diseases
Key Portfolio Product	Encelto
Acquired Technology	Encapsulated-cell therapy platform
Strategic Focus	Retinal disease therapeutics
Payment Structure	Not confirmed in supplied summary
Closing Conditions	Not confirmed in supplied summary
Expected Closing Date	Not confirmed in supplied summary
Geography	Not specified in supplied summary
What Happened	Alcon announced the acquisition of Neurotech Pharmaceuticals for a reported $550 million.
Why It Matters	The transaction broadens Alcon's retinal disease portfolio and adds an encapsulated-cell therapy platform to its ophthalmology capabilities.
Strategic Rationale	Expand beyond Alcon's existing surgical and vision-care businesses into additional retinal therapeutics and drug delivery technologies.
Potential Impact	The acquired platform may support future development and commercialisation of therapies for retinal diseases.
Key Takeaway	Alcon's reported $550 million Neurotech acquisition adds Encelto and encapsulated-cell technology; detailed transaction terms remain unconfirmed in the supplied summary.
What to Watch	Transaction completion, integration of Neurotech, Encelto commercial development and future retinal therapy programmes.
Primary Source	Eyewire News
Primary Source URL	https://eyewire.news/news/alcon-acquires-neurotech-pharmaceuticals-for-550-million-adding-encelto-to-retina-portfolio
Relevant Date	21-22 October 2026

---

Discover how nuaxia can support your next medical education initiative:

• Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector

• Contact us on: support@nuaxia.com